FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis
about
FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacologyA defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosisHIV-1, methamphetamine and astrocytes at neuroinflammatory CrossroadsDefective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammationBenzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MSFingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets.Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis.Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathwaysSphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets.Allogeneic islet transplantation.FTY720 (fingolimod) for relapsing multiple sclerosis.Regulation and functions of sphingosine kinases in the brainEffects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammationProduction and characterization of monoclonal anti-sphingosine-1-phosphate antibodies.Therapeutic applications of bioactive sphingolipids in hematological malignancies.Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.Inflammatory responses in brain ischemia.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720.A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.Quantitative metabolomic and lipidomic profiling reveals aberrant amino acid metabolism in type 2 diabetes
P2860
Q24643383-1A1EFAA4-FFB0-4F31-83EA-93F75A51ACB9Q24644684-435E4346-ABE1-466C-B40C-AB79C7E0CFFBQ28392199-F785C3D4-B9F6-43E1-9952-78FABB426D4CQ33583306-EA68C557-2D20-4915-9CBC-4D1FDFC8A16EQ33598597-B7D7980C-EBAC-4BE8-8BF6-0664022E4B94Q33749104-EAF8B323-8F55-4AA0-A7A4-1A8B0537FC09Q33810559-25A9CB9C-57F5-483B-B3D6-0C5FBAD04557Q33925611-A95579E0-659F-47DA-A9EB-6497D2C15DDFQ34805735-AC9EECBD-2C01-450D-95C6-1D8E43714FBEQ35130512-5762DEA6-3725-4E2A-ACBF-E5CE6BD62572Q35666531-EBE297E9-CB2B-46A9-A9D7-7869875F886FQ36361669-B99DC07B-DF6C-48EB-9BB5-373F4A33A19DQ36636026-2CD5FAE9-F69B-4E28-AA52-275A4235561BQ36840840-D9800F9B-61E9-49E7-B5AC-666B94837850Q36981652-5F534EEC-2975-4442-AE5D-0A3E0021E325Q37154788-9944A649-31CC-4999-94C2-428D39DA609CQ37166130-A71B29A8-9B81-4F88-AF17-464BACF4786AQ37277276-1F990BF7-D9A1-4772-A1AB-B3E506B66165Q37382152-39A6A8EC-1AE3-4CA4-8F5D-00A468370EBAQ37760875-98F676EE-AD99-40A9-958B-92F74AC9C536Q37905767-42A96950-3F48-404E-B822-0CA8078074C6Q38349993-693406E8-DA5E-468C-BA16-C0D6C4F177AEQ38606914-314AAAD9-CFDF-44AE-BA97-D4AD0F819C06Q41911058-C149419E-858C-4DD3-9009-DF312F5C4406Q46792453-DB715B68-6AF7-4463-8829-D2E877522CA3Q57721595-A932A56F-1572-46BF-B165-CC33F81F5FE2
P2860
FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@ast
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@en
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@nl
type
label
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@ast
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@en
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@nl
prefLabel
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@ast
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@en
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@nl
P2093
P2860
P1476
FTY720, an immunomodulatory sp ...... benefit in multiple sclerosis
@en
P2093
Andreas Billich
Thomas Baumruker
Volker Brinkmann
P2860
P356
10.1517/13543784.16.3.283
P407
P577
2007-03-01T00:00:00Z